Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
3Customers
3Debt Items
11Related Chains
Source-Backed Evidence Depth
Armata Pharmaceuticals, Inc. (ARMP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
10High confidence
0.851Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Armata Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
INNOVIVA-STRATEGIC-OPPORTUNITIES-LLC
INNOVIVA-STRATEGIC-OPPORTUNITIES-LLC
92%
On May 13, 2026, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on May 12, 2026, it had entered into, as borrower, a credit and sec…
CFF
CFF
90%
The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfer…
INNOVIVA-SUB
INNOVIVA-SUB
85%
we received the convertible loan (the "Convertible Loan") in the aggregate amount of $30.0 million from Innoviva Sub pursuant to the secured convertible credit and security agreement
MTEC
MTEC
80%
The MTEC Agreement specifies that the award will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the money receiv…
Reciprocal relationship from PHGE graph: ct to adjustments. Accordingly, subject to receipt of approval of the stockholders of the Company, the Investor will beneficially own the majority of the shar…
Armata Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
CFF
CFF
90%
The Company entered into an award agreement (the “Award Agreement”) with the CFF, pursuant to which the Company received a Therapeutics Development Award of up to $ 5.0 million (the “CFF Award”).
MTEC
MTEC
90%
The Company recognized $ 0.8 million and $ 0.5 million in grant and award revenue from the MTEC Agreement during the three months ended March 31, 2026 and 2025, respectively.
LIQUIDITY-CAPITAL-RESOURCES
LIQUIDITY-CAPITAL-RESOURCES
62%
ed to increased debt balances as compared to the prior year period. Interest expense related to the amortization of debt discount and issuance costs for the secured term loan facility in an aggregate…
Armata Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ARMP-DEBT
Debt stack $373.7M
90%
Market cache reports total debt of $373.7M.
ARMP-DEBT-7850
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
ARMP-DEBT-7849
Warrants outstanding: 393939
90%
xbrl warrant detail from xbrl 2020-12-31.
Armata Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Armata Pharmaceuticals, Inc..
Armata Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ARMP-OWNER-MADISON-ASSET-MANAGEMENT-LLC
Madison Asset Management, LLC
90%
13F overlay lists Madison Asset Management, LLC as top holder; 45 tracked holders.
Armata Pharmaceuticals, Inc. Extended Supply Chain Network
